glucose, (beta-d)-isomer has been researched along with Atheroma in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 9 (64.29) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, W; Jia, Y; Li, H; Li, X; Liao, Y; Liu, K; Tan, Z; Tian, G; Yuan, Z; Zhang, H; Zhang, Y | 1 |
| Chen, YC; Jandeleit-Dahm, K; Peter, K | 1 |
| Katakami, N; Maeda, N; Mita, T; Sato, Y; Shimomura, I; Watada, H | 1 |
| Cao, Z; Dong, X; Fu, J; Tu, Q; Wu, F; Xie, H; Xu, H | 1 |
| Anto-Michel, N; Bode, C; Füner, L; Gissler, MC; Goldberg, IJ; Härdtner, C; Hilgendorf, I; Hoppe, N; Mullick, A; Pennig, J; Scherrer, P; Stachon, P; Willecke, F; Wolf, D; Zirlik, A | 1 |
| Chen, L; Lei, X; Li, J; Li, WJ; Liu, X; Wang, K; Xing, SS; Yang, J; Yang, YT | 1 |
| Fukuda, D; Ganbaatar, B; Hirata, KI; Kusunose, K; Sata, M; Shinohara, M; Soeki, T; Yagi, S; Yamada, H | 1 |
| Ahmad, P; Alvi, SS; Iqbal, D; Khan, MS | 1 |
| Li, X; Liu, L; Wang, S; Wu, M; Xing, Y; Yang, S; Zhao, R | 1 |
| Chen, X; Hu, Y; Jing, Y; Li, H; Liang, J; Shi, Y; Wu, J; Xiong, Q; Yan, Z; Yuan, J; Zhang, Q; Zhou, L | 1 |
| Aguilar-Ballester, M; Burks, DJ; González-Navarro, H; Herrero-Cervera, A; Martínez-Hervás, S; Real, JT; Taberner-Cortés, A; Vinué, Á | 1 |
| Aihara, KI; Higashiguchi, F; Katagi, A; Kitagawa, T; Kurobe, H; Nakayama, T; Nishio, C; Sata, M; Shimabukuro, M; Sugasawa, N; Takumi, H | 1 |
| Agrogiannis, G; Dimitriadis, GK; Kaltsas, G; Kassi, E; Kostakis, ID; Nasiri-Ansari, N; Nikiteas, N; Papavassiliou, AG; Patel, VH; Randeva, HS; Randeva, MS | 1 |
| Cuong, TD; Jeon, BH; Lee, JH; Min, B; Ryoo, S; Shin, W; Woo, A | 1 |
2 review(s) available for glucose, (beta-d)-isomer and Atheroma
| Article | Year |
|---|---|
Insights into pharmacological mechanisms of polydatin in targeting risk factors-mediated atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Endothelial Cells; Fallopia japonica; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, LDL; Plaque, Atherosclerotic; Receptors, LDL; Risk Factors; Stilbenes | 2020 |
Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Arteries; Atherosclerosis; Cardiovascular Agents; Glucosides; Humans; Inflammation Mediators; Lipid Metabolism; Oxidative Stress; Plaque, Atherosclerotic; Signal Transduction; Stilbenes | 2020 |
1 trial(s) available for glucose, (beta-d)-isomer and Atheroma
| Article | Year |
|---|---|
Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
Topics: Adult; Aged; Benzhydryl Compounds; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2022 |
11 other study(ies) available for glucose, (beta-d)-isomer and Atheroma
| Article | Year |
|---|---|
Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-κB translocation.
Topics: Animals; Aorta; Atherosclerosis; Biological Transport; Disease Models, Animal; Foam Cells; Focal Adhesion Kinase 1; Integrins; Male; NF-kappa B; Panax notoginseng; Phosphorylation; Phytotherapy; Plant Extracts; Plaque, Atherosclerotic; Rats; Rats, Wistar; Saponins; Threonine; Zymosan | 2011 |
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability.
Topics: Animals; Benzhydryl Compounds; Constriction, Pathologic; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose; Glucosides; Humans; Hypoglycemic Agents; Mice; Plaque, Atherosclerotic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2022 |
Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
Topics: Adenosine; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Glucosides; Inflammation; Lipoproteins, LDL; Macrophages; Mice; NF-kappa B; Plaque, Atherosclerotic; RNA; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucosides; Male; Mice; Mice, Inbred C57BL; Plaque, Atherosclerotic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Salidroside Decreases Atherosclerosis Plaque Formation via Inhibiting Endothelial Cell Pyroptosis.
Topics: Animals; Atherosclerosis; Dose-Response Relationship, Drug; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Knockout; Phenols; Plaque, Atherosclerotic; Pyroptosis; Rhodiola | 2020 |
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Eicosanoids; Endothelium, Vascular; Glucosides; Humans; Male; Mice; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2020 |
Polydatin alleviates high-fat diet induced atherosclerosis in apolipoprotein E-deficient mice by autophagic restoration.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Autophagy; Diet, High-Fat; Glucosides; Male; Mice, Knockout, ApoE; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-akt; Stilbenes; TOR Serine-Threonine Kinases | 2021 |
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Computational Biology; Disease Models, Animal; Fasting; Glucose; Glucosides; Immunohistochemistry; Insulin Resistance; Macrophages; Mice; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Inhibition of Atherosclerotic Plaque Development by Oral Administration of α-Glucosyl Hesperidin and Water-Dispersible Hesperetin in Apolipoprotein E Knockout Mice.
Topics: Administration, Oral; Animals; Antioxidants; Apolipoproteins E; Cholesterol; Diet, High-Fat; Glucosides; Hesperidin; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic | 2019 |
Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice.
Topics: Administration, Oral; Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diastole; Diet, High-Fat; Fasting; Glucosides; Heart Rate; Hemodynamics; Lipids; Metalloproteases; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; RNA, Messenger | 2019 |
Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet.
Topics: Analysis of Variance; Animals; Aorta; Apolipoproteins E; Arginase; Diet, High-Fat; Enzyme Stability; Glucosides; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Stilbenes; Vasoconstriction | 2013 |